You are here

  • Home
  • Archive
  • Volume 73, Issue 9
  • HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al

Article Text

Article menu
PDF
Electronic pages
Correspondence response
HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al
  1. David Saadoun,
  2. Patrice Cacoub
  1. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d'Immunologie clinique, Centre national de référence maladies systémiques et autoimmunes rares, DHU Inflammation, Immunopathologie, Biothérapie, Université Paris VI—Pierre et Marie Curie, Paris, France
  1. Correspondence to Dr David Saadoun, Département de Médecine Interne et d'Immunologie clinique, Groupe Hospitalier Pitié-Salpêtrière, 84, boulevard de l'Hôpital, Paris 75013, France; david.saadoun{at}psl.aphp.fr

http://dx.doi.org/10.1136/annrheumdis-2014-206022

Statistics from Altmetric.com

    We thank Ignatova and colleagues1 for their interest in our work regarding peginterferonα-ribavirin/protease inhibitor combination in hepatitis C virus-associated mixed cryoglobulinaemia vasculitis (HCV-MC),2 and in bringing new elements up for discussion.

    Ignatova et al emphasise the priority to clear the virus in HCV-MC. They reported 65 patients with HCV-associated MC vasculitis who were treated with conventional immunosuppresive drugs only (n=30), monotherapy with interferon-alfa (n=9) or rituximab (n=8) or peginterferon-alfa/ribavirin±rituximab …

    View Full Text

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

    Linked Articles